Celadon Pharmaceuticals Plc
("Celadon" or the "Company")
Publication of Annual Report and Notice of Annual General Meeting
London, 3 June 2024- Celadon Pharmaceuticals Plc, a leading UK based pharmaceutical company focused on the development and supply of natural cannabis-based medicines, announces that copies of the 2023 Annual Report and Accounts, together with its Notice of 2024 Annual General Meeting ("AGM"), were posted to shareholders today and are available for viewing on the Company's website www.celadonpharma.com.
The Company will be holding its AGM at 12 noon on Thursday 27 June 2024 at the offices of Gowling WLG (UK) LLP, 4 More London Riverside, London SE1 2AU.
Enquiries:
| Celadon Pharmaceuticals Plc |
|
| James Short Jonathan Turner | Via Powerscourt |
| | |
| Canaccord Genuity Limited (Nominated Adviser and Broker) | |
| Bobbie Hilliam/Andrew Potts | +44 (0)20 7523 8000 |
| Global Investment Strategy UK Limited (Joint Broker) James Sheehan |
+44 (0)20 7048 9400 |
| Powerscourt Group | |
| Sarah MacLeod / Nick Johnson / Sam Austrums | +44 (0)20 7250 1446
|
About Celadon Pharmaceuticals Plc
Celadon Pharmaceuticals Plc is a UK based pharmaceutical company focused on the research, cultivation, manufacturing, and sale of breakthrough cannabis-based medicines. Its primary focus is on improving quality of life for chronic pain sufferers, as well as exploring the potential of cannabis-based medicines for other conditions such as autism. Its 100,000 sq. ft UK facility is EU-GMP approved and comprises indoor hydroponic cultivation, proprietary GMP extraction and manufacturing and an analytical and R&D laboratory. Celadon's Home Office licence allows for the commercial supply of its GMP pharmaceutical cannabis product. The Group owns an approved clinical trial using cannabis based medicinal products to treat chronic pain in the UK. Celadon also has a minority interest in early-stage biopharma Kingdom Therapeutics which is developing a licensed cannabinoid medicine to treat children with Autism Spectrum Disorder.
For further information please visit our website www.celadonpharma.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.